B. Metzler seel. Sohn & Co. Holding AG Invests $2.22 Million in Insulet Co. (NASDAQ:PODD)

B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Insulet Co. (NASDAQ:PODD) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 9,542 shares of the medical instruments supplier’s stock, valued at approximately $2,221,000.

Other hedge funds also recently bought and sold shares of the company. Baillie Gifford & Co. raised its holdings in Insulet by 20.7% in the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after buying an additional 389,639 shares during the last quarter. Clearbridge Investments LLC raised its holdings in Insulet by 6.0% in the 2nd quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after acquiring an additional 75,526 shares during the last quarter. American Century Companies Inc. lifted its position in Insulet by 18.7% in the 2nd quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock valued at $178,728,000 after acquiring an additional 139,246 shares in the last quarter. Marshall Wace LLP purchased a new stake in Insulet during the 2nd quarter valued at $99,978,000. Finally, Canada Pension Plan Investment Board increased its holdings in shares of Insulet by 206.9% in the 1st quarter. Canada Pension Plan Investment Board now owns 429,591 shares of the medical instruments supplier’s stock worth $73,632,000 after purchasing an additional 289,591 shares in the last quarter.

Insulet Stock Down 1.3 %

NASDAQ PODD opened at $262.99 on Friday. The stock’s 50-day moving average price is $240.74 and its 200-day moving average price is $209.99. The company has a market capitalization of $18.45 billion, a P/E ratio of 45.03, a price-to-earnings-growth ratio of 4.01 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PODD shares. Canaccord Genuity Group upped their price target on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Barclays upped their target price on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler lifted their price target on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Citigroup increased their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. Finally, BTIG Research lifted their target price on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.